高分子载体α，β－聚（羟烷基）－DL－天冬酰胺的合成及分子量测定

以ＤＬ－天冬氨酸为单体，聚合成ＤＬ－天冬酸胺，接入不同悬臂氨基乙醇，氨基内醇，氨基丁醇，得到α，β－聚（羟烷基）－ＤＬ－天冬酰胺，分别是α，β－聚（２－羟乙基）－ＤＬ－大冬酰胺（ＰＨＥＡ），α，β－聚（３－羟丙基）－ＤＬ－天冬酰胺（ＰＨＰＡ），α，β－聚（４－羟丁基）－ＤＬ－天冬酰胺（ＰＨＢＡ）。用红外光谱表征了高分子载体，比较了不同投料比对反应的影响；测定了高分子载体的比浓粘度，建立了ＰＨＰＡ的Ｍａｒｋ—Ｈｏｕｗｉｎｋ方程。     

侧链含咪唑取代基聚(L-天冬酰胺)高效基因载体研究

通过氨基引发聚丁二酰亚胺( PSI)开环反应,制备了系列侧链含氨乙基和咪唑丙基的聚(L-天冬酰胺)共聚物(P1 ～ P5).该系列聚合物不仅具有极低的细胞毒性,而且随侧链中咪唑取代基含量的增加,聚合物在pH 5 ～8范围内缓冲能力显著提高.通过凝胶电泳、粒径和电位分析等研究了聚合物与质粒DNA的相互作用.结果表明,所有...     

胆固醇修饰的低分子量聚乙烯亚胺接枝化聚[L-天冬酰胺-co-L-赖氨酸]作为基因载体的性能研究

通过将低分子量的聚乙烯亚胺(PEI600)及其胆固醇衍生物与聚(L-天冬酰胺-co-L-赖氨酸)(PSL)进行开环反应, 合成了一类新型的肿瘤靶向基因载体, 研究了这类载体与DNA形成复合物的性质以及介导绿色荧光蛋白质粒pEGFP-C1转染不同细胞的性能. 结果表明, 在复合质量比大于5∶1时, 各载体均能与DNA形成结构稳定的复合物. 同时转染实验结果证明, 通过在侧链引入一定数目的胆固醇, 可以明显提高载体对于癌细胞HepG2和Hela的转染效率. 这类新型的载体具有良好的细胞相容性、较高的转染效率以及易于进行靶向修饰等特点, 在基因治疗研究领域中将具有较好的潜在应用价值.     

α,β-聚-DL-天冬酰胺衍生物水凝胶的合成及其溶胀性能研究

以ＤＬ 天冬氨酸为单体，通过缩合聚合反应合成聚 ＤＬ 丁二酰亚胺，然后用不同比例的乙醇胺和丁二胺进行开环和交联，获得α，β 聚 ＤＬ 天冬酰胺衍生物水凝胶．测定了水凝胶在几种不同溶液中的溶胀比，结果表明该水凝胶在蒸馏水中的溶胀比为１１０～４４０倍，在不同浓度的盐溶液中的溶胀比有不同程度的降低，在０１６ｍｏｌ／Ｌ的抗肿瘤药物５ 氟尿嘧啶（５ Ｆｕ）水溶液中的溶胀比可达１４０倍．研究了聚丁二酰亚胺分子量、溶剂用量及交联剂用量等因素对凝胶溶胀性能的影响．     

响应性聚合物纳米材料作为药物载体的研究进展

近年来聚合物纳米材料被应用于药物递送系统的研究,其中刺激响应性聚合物纳米载体因具有载药稳定性好、生物相容性好等特点而成为研究热点,通过各种内在或外在条件给予适当刺激,响应性聚合物纳米载体能达到药物控制释放的目的.本文介绍了几种单一刺激和多重刺激响应性聚合物材料的研究进展及作为抗癌药物载体的优势,并对未来的发展方向进行了...     

聚天冬酰胺键合布洛芬共价复合体的合成

聚天冬酰胺类高分子材料,以其生物相容性好,毒性低,合成路线简单,且易与药物键合,被认为是一类有相当前景的药物控制释放材料,已引起国内外学者的极大兴趣［１,２］。课题组已对该材料进行了多年的研究,成功地将乙酰水杨酸、炔诺酮等多种药物键合于该材料上［３－...     

用于基因和药物传递的多肽及聚多肽材料

多肽和聚多肽作为一类新型的生物医用材料,由于其具有良好的生物活性、生物可降解性以及生物相容性而备受瞩目.将具有特殊生理功能的多肽作为基因或药物载体、或用于药物修饰等,可以提高基因转染效率,增强药物的靶向治疗效果,降低药物的毒副作用.本文综述了近年来多肽及聚多肽材料在这些生物医学领域的应用及进展,对部分活性肽的作用机制和...     

生物高分子聚苹果酸及其衍生物的合成与应用前景

生物高分子对生命过程十分重要,它们表现出了卓越的特性和潜在的应用前景,因而一直是国内外学者的一个新的研究热点。聚苹果酸及其衍生物作为一类新型的生物高分子同样具有一些独特的性质。本文介绍了聚苹果酸及其衍生物的结构和性能特点,全面综述了它们的合成与制备方法研究的进展,展示了它们作为生物医用材料在药物释放体系、组织工程等领域中的应用前景。     

碳纳米管在药物和基因转运领域的研究进展

当前,国内外的许多研究小组都致力于开发出新型有效的药物和基因转运系统,用于改善多种治疗因子的药理学作用并降低其毒性。在纳米材料这一类中,碳纳米管（Carbon Nanotubes, CNTs）正逐步引起人们的关注。功能化的CNTs的两个关键优势在于它具有很强的细胞穿透能力和较低的细胞毒性,使其在药物和基因转运领域中的应用成为可能。CNTs可通过形成稳定的共价键或形成以非共价键为基础的超分子结合物来运载肽类、蛋白质、核酸和药物等活性分子,并将其运送至特定的组织、器官中以表达特殊的生物学功能。针对这一研究热点,本文综述了近几年国内外关于碳纳米管在药物和基因转运领域中的应用进展,并探讨了其毒性,以期为这一领域中的研究工作者提供参考。     

荧光介孔二氧化硅纳米粒子的合成及药物运输

合成了荧光介孔二氧化硅纳米粒子（MSNs-FITC）,并研究了其在持续药物释放和生物示踪成像方面的应用。首先,采用一步法合成出MSNs-FITC,结合SEM、TEM、FT-IR、XRD和氮气吸附脱附等表征技术进行表征。其次,将抗癌药物阿霉素（DOX）负载到MSNs-FITC中。载药粒子的药物释放行为具有明显的pH依赖性,酸性环境加速释放速率。同时,体外细胞毒性测试表明MSNs-FITC具有良好的生物相容性。激光共聚焦扫描显微镜（CLSM）图像表明,MSNs-FITC可以进入细胞并具有剂量依赖性,流式细胞术分析（FCM）进一步证明了这一结果。     

空心纳米磷酸钙载药体系的制备与表征

非离子表面活性剂Tween 80和PEG 6000在水溶液中以一定的比例混合可形成稳定的类磷脂囊泡结构,这些囊泡可以作为模板来合成磷酸钙纳米空球颗粒。所制备的磷酸钙材料的结构和形貌通过TEM,SEM,FTIR,XRD进行了表征,是尺寸为100～150 nm左右的无定形磷酸钙空心颗粒。磷酸钙具有良好的生物相容性,因此这些具有空心结构特征的磷酸钙可发展为理想的载药体系。我们以牛血清蛋白(BSA)为模型体系研究了材料的载药和释放性能,发现所获得的空心纳米磷酸钙不仅具有良好的蛋白质负载量而且还具有优异的可释放性,明显优于传统的羟基磷灰石体系。     

Nanomaterials for Ocular Drug Delivery

Efficient drug delivery to the eye remains a challenging task for pharmaceutical scientists. Due to the various anatomical barriers and the clearance mechanisms prevailing in the eye, conventional drug delivery systems, such as eye drop solutions, suffer from low bioavailability. More invasive methods, such as intravitreal injections and implants, cause adverse effects in the eye. Recently, an increasing number of scientists have turned to nanomaterial‐based drug delivery systems to address the challenges faced by conventional methods. This paper highlights recent applications of various nanomaterials, such as polymeric micelles, hydrogels, liposomes, niosomes, dendrimers, and cyclodextrins as ocular drug delivery systems to enhance the bioavailability of ocular therapeutic agents.

     

肽类树状大分子的合成及其在药物传输系统中的应用

树状大分子是近年来蓬勃发展的一类新型高分子材料, 其表面存在大量的官能团, 分子内部存在空腔且分子尺寸可控, 因此, 树状大分子已被广泛应用于众多的领域. 肽类树状大分子是指在树状大分子结构中含有肽键的一类大分子, 因其具有类似蛋白质一样的球状结构, 且具有优异的水溶性、生物相容性、生物降解性和细胞低毒性等特点, 所以, 肽类树状大分子可以作为药物传输的载体. 此外, 肽类树状大分子的疏水空腔可以装载疏水性药物, 对其起到增溶和缓释作用. 综述了肽类树状大分子的合成方法, 并对其与药物分子的结合机制及其在药物传输系统中的应用进行了总结与展望.     

Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases

Advanced drug delivery micro- and nanosystems have been widely explored due to their appealing specificity/selectivity, biodegradability, biocompatibility, and low toxicity. They can be applied for the targeted delivery of pharmaceuticals, with the benefits of good biocompatibility/stability, non-immunogenicity, large surface area, high drug loading capacity, and low leakage of drugs. Cardiovascular diseases, as one of the primary mortalities cause worldwide with significant impacts on the quality of patients’ life, comprise a variety of heart and circulatory system pathologies, such as peripheral vascular diseases, myocardial infarction, heart failure, and coronary artery diseases. Designing novel micro- and nanosystems with suitable targeting properties and smart release behaviors can help circumvent crucial challenges of the tolerability, low stability, high toxicity, and possible side- and off-target effects of conventional drug delivery routes. To overcome different challenging issues, namely physiological barriers, low efficiency of drugs, and possible adverse side effects, various biomaterials-mediated drug delivery systems have been formulated with reduced toxicity, improved pharmacokinetics, high bioavailability, sustained release behavior, and enhanced therapeutic efficacy for targeted therapy of cardiovascular diseases. Despite the existing drug delivery systems encompassing a variety of biomaterials for treating cardiovascular diseases, the number of formulations currently approved for clinical use is limited due to the regulatory and experimental obstacles. Herein, the most recent advancements in drug delivery micro- and nanosystems designed from different biomaterials for the treatment of cardiovascular diseases are deliberated, with a focus on the important challenges and future perspectives.     

Synthesis of Cholesterylated Thiogalactosides for Gene Delivery

A series of cholesterylated thiogalactosides L₁ –L₆ the cell targeting ligands for gene delivery to hepatocytes, was synthesized. Related poly(ethylene glycol) chain was used as a bridge for the attachment of galactoside on one hydroxyl end, while the other hydroxyl end was linked with cholesterol. This design provided an effective entry for the synthesis of a poly(ethylene glycol) compound with the hepatocyte targeting.     

纳米粒子在药物传递中的应用

目前,利用纳米粒子传递药物并用于恶性肿瘤组织的靶向识别,进一步提高肿瘤的诊断和治疗水平是一个比较热点的领域,人们期望用制备容易、价格便宜、毒性小的纳米技术来提高肿瘤的治疗效率。然而,由近年的报道来看,所摄入的纳米粒子仅有约0.7%能够到达肿瘤部位,传递效率较低,这无疑加大了治疗应用的难度。本综述中,我们分析了造成纳米粒子靶向药物转运效率较低的原因,包括纳米粒子的转运途径,纳米粒子转运过程中所遇到的屏障,纳米粒子在体内的清除途径等;随后我们介绍了较早应用的聚合物纳米粒子、磁性氧化铁纳米粒子以及目前广泛研究的介孔二氧化硅纳米粒子在药物传递系统构建中的应用情况,还介绍了细胞膜仿生纳米粒子在药物传递系统中的应用;最后,对纳米粒子在药物传递中的研究进行总结和展望。我们希望通过对纳米粒子传递药物的系统研究,进一步促进纳米粒子在药物传递上的研究,加速纳米药物的临床应用。     

Photomechanical Polymer Nanocomposites for Drug Delivery Devices

We demonstrate a novel structure based on smart carbon nanocomposites intended for fabricating laser-triggered drug delivery devices (DDDs). The performance of the devices relies on nanocomposites’ photothermal effects that are based on polydimethylsiloxane (PDMS) with carbon nanoparticles (CNPs). Upon evaluating the main features of the nanocomposites through physicochemical and photomechanical characterizations, we identified the main photomechanical features to be considered for selecting a nanocomposite for the DDDs. The capabilities of the PDMS/CNPs prototypes for drug delivery were tested using rhodamine-B (Rh-B) as a marker solution, allowing for visualizing and quantifying the release of the marker contained within the device. Our results showed that the DDDs readily expel the Rh-B from the reservoir upon laser irradiation and the amount of released Rh-B depends on the exposure time. Additionally, we identified two main Rh-B release mechanisms, the first one is based on the device elastic deformation and the second one is based on bubble generation and its expansion into the device. Both mechanisms were further elucidated through numerical simulations and compared with the experimental results. These promising results demonstrate that an inexpensive nanocomposite such as PDMS/CNPs can serve as a foundation for novel DDDs with spatial and temporal release control through laser irradiation.     

Integrated Hollow Mesoporous Silica Nanoparticles for Target Drug/siRNA Co‐Delivery

A hollow mesoporous silica nanoparticle (HMSNP) based drug/siRNA co‐delivery system was designed and fabricated, aiming at overcoming multidrug resistance (MDR) in cancer cells for targeted cancer therapy. The as‐prepared HMSNPs have perpendicular nanochannels connecting to the internal hollow cores, thereby facilitating drug loading and release. The extra volume of the hollow core enhances the drug loading capacity by two folds as compared with conventional mesoporous silica nanoparticles (MSNPs). Folic acid conjugated polyethyleneimine (PEI‐FA) was coated on the HMSNP surfaces under neutral conditions through electrostatic interactions between the partially charged amino groups of PEI‐FA and the phosphate groups on the HMSNP surfaces, blocking the mesopores and preventing the loaded drugs from leakage. Folic acid acts as the targeting ligand that enables the co‐delivery system to selectively bind with and enter into the target cancer cells. PEI‐FA‐coated HMSNPs show enhanced siRNA binding capability on account of electrostatic interactions between the amino groups of PEI‐FA and siRNA, as compared with that of MSNPs. The electrostatic interactions provide the feasibility of pH‐controlled release. In vitro pH‐responsive drug/siRNA co‐delivery experiments were conducted on HeLa cell lines with high folic acid receptor expression and MCF‐7 cell lines with low folic acid receptor expression for comparison, showing effective target delivery to the HeLa cells through folic acid receptor meditated cellular endocytosis. The pH‐responsive intracellular drug/siRNA release greatly minimizes the prerelease and possible side effects of the delivery system. By simultaneously delivering both doxorubicin (Dox) and siRNA against the Bcl‐2 protein into the HeLa cells, the expression of the anti‐apoptotic protein Bcl‐2 was successfully suppressed, leading to an enhanced therapeutic efficacy. Thus, the present multifunctional nanoparticles show promising potentials for controlled and targeted drug and gene co‐delivery in cancer treatment.